Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ACELRX PHARMA (NQ: ACRX)
6.460 USD  UNCHANGED
Official Closing Price  /  Updated: 8:10 PM EDT, May 20, 2013  /  Add to My Watchlist      
View: Quote News
Press releases about ACELRX PHARMA
 
< Previous 1 2 Next >
AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
May 16, 2013
from PR Newswire
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
May 08, 2013
from PR Newswire
AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
May 03, 2013
from PR Newswire
AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
May 02, 2013
- Additional Phase 3 analysis show significantly faster reduction in pain and fewer patients with oxygen desaturation events for Sufentanil NanoTab PCA System than IV PCA with morphine - Read More
from PR Newswire
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
April 24, 2013
- Patients in the 30 mcg sufentanil NanoTab treatment group experienced significantly greater reduction in pain as measured by SPID-12 vs. placebo - Read More
from PR Newswire
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
March 12, 2013
from PR Newswire
AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
March 07, 2013
from PR Newswire
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
March 04, 2013
- Patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p=0.001) - Read More
from PR Newswire
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
February 27, 2013
from PR Newswire
AcelRx Pharmaceuticals Provides Clinical Trial Updates
February 19, 2013
Continued progress towards NDA submission for Sufentanil NanoTab PCA System in Q3 2013 Read More
from PR Newswire
AcelRx Appoints Adrian Adams to Board of Directors as Chairman
February 12, 2013
from PR Newswire
Foresite Capital Management Closes $100 Million Growth Capital Fund to Finance Late-Stage Healthcare Companies
January 31, 2013
from Marketwired News Releases
Perfect Trade Setups, How to Play ACRX, ENMD, NLY and WPI
January 23, 2013
from Marketwired News Releases
The Real Story Behind ACRX, ROSG and PPHM
January 02, 2013
from Marketwired News Releases
AcelRx Pharmaceuticals Announces Exercise of Option to Purchase Additional Shares
December 14, 2012
from PR Newswire
AcelRx to Present Top-Line Data from Phase 3 Study of Sufentanil NanoTab® PCA System vs. IV PCA Morphine at the 66th Annual PostGraduate Assembly in Anesthesiology held in New York City
December 14, 2012
- First medical meeting presentation of top-line Phase 3 data demonstrating NanoTab System met both non-inferiority and superiority comparisons to IV PCA with morphine in open-label study - Read More
from PR Newswire
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
December 06, 2012
from PR Newswire
AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
December 05, 2012
from PR Newswire
AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
November 20, 2012
from PR Newswire
AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain
November 15, 2012
-In this open-label study, the Sufentanil NanoTab PCA System also demonstrated statistical superiority to IV PCA morphine for primary endpoint of Patient Global Assessment of method of pain control Read More
from PR Newswire
AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-L
November 14, 2012
from PR Newswire
AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
November 06, 2012
from PR Newswire
AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
November 05, 2012
- Phase 2 placebo-controlled, dose-finding study funded by a grant from the Department of Defense - Read More
from PR Newswire
AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
November 01, 2012
from PR Newswire
AcelRx Receives Notice of Eligibility for Centralized Review from European Medicines Agency for the Sufentanil NanoTab® PCA System
October 03, 2012
Centralized review process used for products that provide a significant therapeutic, scientific or technical innovation to patient health Read More
from PR Newswire
AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
September 18, 2012
from PR Newswire
AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
September 10, 2012
from PR Newswire
AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
August 29, 2012
Two more U.S. patents expand intellectual property protection for AcelRx's pipeline of sufentanil NanoTab® pain products Read More
from PR Newswire
AcelRx Pharmaceuticals Initiates Third Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab® PCA System, for the Treatment of Post-Operative Pain
August 23, 2012
First orthopedic surgery patient dosed in randomized, double-blind, placebo-controlled trial Read More
from PR Newswire
AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
August 23, 2012
from PR Newswire
< Previous 1 2 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here